Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new antibody therapeutics for oncology.
Apexigen has raised $2.8M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2023.
Apexigen's investors include Decheng Capital, 3E Bioventures, Delian Capital, Oceanpine Capital, SV Tech Ventures.
Apexigen is headquartered in San Carlos, United States.
Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new antibody therapeutics for oncology.
Apexigen is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Apexigen — Funding & Investors." VCBacked, January 24, 2023, https://www.vcbacked.co/company/apexigen. Accessed August 14, 2026.
VCBacked. (2023). Apexigen — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/apexigen
{{cite web |title=Apexigen — Funding & Investors |url=https://www.vcbacked.co/company/apexigen |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated